Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.3K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.2K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

941
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
941
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

203
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
203

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Primary Care Physician Continuity on Survival in Patients with Atrial Fibrillation: A Retrospective Cohort Study.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.

European heart journal open·2026
Same author

GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

Biomarkers and Prognosis After Myocardial Infarction: Towards Precision Cardiology.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

International journal of clinical pharmacy·2026
Same author

Neural stem cells and glioblastoma stem cells: Redefining concepts.

Critical reviews in oncology/hematology·2026

Related Experiment Video

Updated: Dec 19, 2025

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

8.8K

Edoxaban's contribution to key endothelial cell functions.

Cristina Almengló1, Nerea Mosquera-Garrote1, Mercedes González-Peteiro2

  • 1Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain.

Biochemical Pharmacology
|June 4, 2020
PubMed
Summary

Edoxaban, a factor Xa inhibitor, supports endothelial cell functions, reducing inflammation and promoting cardiovascular health by influencing key signaling pathways.

Keywords:
EdoxabanHuman endothelial cells key functionsInflammatory endothelial reactionPBMC adhesionWound-healing

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K
Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

1.0K

Related Experiment Videos

Last Updated: Dec 19, 2025

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

8.8K
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K
Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

1.0K

Area of Science:

  • Cardiovascular Science
  • Endothelial Biology
  • Pharmacology

Background:

  • Endothelial dysfunction contributes to cardiovascular disease.
  • New anticoagulants are evaluated for their impact on endothelial health.
  • Edoxaban is an oral anticoagulant targeting Factor Xa (FXa).

Purpose of the Study:

  • To investigate the effects of edoxaban on endothelial cell functions.
  • To assess edoxaban's potential cardiovascular benefits through endothelial modulation.
  • To elucidate the molecular mechanisms underlying edoxaban's endothelial effects.

Main Methods:

  • Human umbilical endothelial cells (HUVEC) were used to assess cell proliferation, migration, and angiogenesis.
  • Mononuclear cell (PBMC) and platelet adhesion assays were performed.
  • Gene and protein expression analyses identified key molecular pathways, including PI3K/AKT and NF-kB.

Main Results:

  • Edoxaban enhanced HUVEC viability and growth, counteracting FXa's antiangiogenic effects via the PI3K/AKT pathway.
  • Edoxaban inhibited PBMC adhesion and transmigration, and reduced platelet adhesion to HUVEC.
  • Edoxaban modulated FXa-induced inflammatory responses through the PAR 1-2/PI3K/NF-kB pathway.

Conclusions:

  • Edoxaban stabilizes endothelial cells and exhibits anti-inflammatory properties.
  • Edoxaban may contribute to hemostasis by reducing platelet adhesion.
  • Edoxaban's primary molecular mechanism involves regulating PI3K/NF-kB pathways.